{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:08:05Z","timestamp":1790633285624,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T00:00:00Z","timestamp":1483920000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s40261-016-0481-0","type":"journal-article","created":{"date-parts":[[2017,1,8]],"date-time":"2017-01-08T20:44:22Z","timestamp":1483908262000},"page":"259-272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1039-378X","authenticated-orcid":false,"given":"Robert","family":"Kimutai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Njoroge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Omollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asrat","family":"Hailu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eltahir A. G.","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ermias","family":"Diro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peninah","family":"Soipei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brima","family":"Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Salman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koert","family":"Ritmeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Chappuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juma","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rezika","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asfaw","family":"Jameneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyasu","family":"Makonnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Olobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Okello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Sagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Strub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Alvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manica","family":"Balasegaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Alirol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Wasunna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,9]]},"reference":[{"issue":"11","key":"481_CR1","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/nrmicro1748","volume":"5","author":"F Chappuis","year":"2007","unstructured":"Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol. 2007;5(11):S7\u201316.","journal-title":"Nat Rev Microbiol."},{"issue":"5","key":"481_CR2","doi-asserted-by":"crossref","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","volume":"7","author":"J Alvar","year":"2012","unstructured":"Alvar J, V\u00e9lez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671.","journal-title":"PLoS One."},{"key":"481_CR3","doi-asserted-by":"crossref","unstructured":"Paul R. Epidemiology of visceral leishmaniasis. Clin Epidemiol. 2016;(May 2014):147\u201354.","DOI":"10.2147\/CLEP.S44267"},{"issue":"22","key":"481_CR4","first-page":"1","volume":"1996","author":"RD Pearson","year":"1995","unstructured":"Pearson RD, Sousa ADQ. Clinical spectrum of leishmaniasis. Clin Infect Dis. 1995;1996(22):1\u201313.","journal-title":"Clin Infect Dis."},{"issue":"4","key":"481_CR5","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/ije\/25.4.862","volume":"25","author":"J Seaman","year":"1996","unstructured":"Seaman J, Mercer AJ, Sondorp E. The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994. Int J Epidemiol. 1996;25(4):862\u201371.","journal-title":"Int J Epidemiol."},{"key":"481_CR6","first-page":"11","volume":"2013","author":"E Awad","year":"2013","unstructured":"Awad E, Khalil G, Khidir SA, Musa AM, Musa BY, Elfaki M, et al. A paradigm of paradoxical immune reconstitution syndrome in non-HIV\/AIDS patients. J Trop Med. 2013;2013:11\u20136.","journal-title":"J Trop Med."},{"key":"481_CR7","doi-asserted-by":"crossref","unstructured":"Khalil EAG, Zijlstra EE, Kager PA, El Hassan AM. Epidemiology and clinical manifestations of Leishmania donovani infection in two villages in an endemic area in eastern Sudan. Trop Med Int Health. 2002;7(1):35\u201344.","DOI":"10.1046\/j.1365-3156.2002.00832.x"},{"issue":"February","key":"481_CR8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1473-3099(03)00517-6","volume":"3","author":"EE Zijlstra","year":"2003","unstructured":"Zijlstra EE, Musa AM, Khalil EAG, El Hassan IM. Review post-kala-azar dermal leishmaniasis. Lancet Infect Dis. 2003;3(February):87\u201398.","journal-title":"Lancet Infect Dis."},{"issue":"9","key":"481_CR9","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1046\/j.1365-3156.2001.00776.x","volume":"6","author":"Hassan AM El","year":"2001","unstructured":"El Hassan AM, Khalil EAG. Short communication: post-kala-azar dermal leishmaniasis: does it play a role in the transmission of Leishmania donovani in the Sudan? Trop Med Int Health. 2001;6(9):743\u20134.","journal-title":"Trop Med Int Health."},{"issue":"9185","key":"481_CR10","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(98)10178-2","volume":"354","author":"BL Herwaldt","year":"1999","unstructured":"Herwaldt BL. Leishmaniasis. Lancet. 1999;354(9185):1191\u20139.","journal-title":"Lancet."},{"key":"481_CR11","unstructured":"World Health Organization. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases. WHO TRS N\u00b0 949 March 2010. Available from: http:\/\/apps.who.int\/iris\/bitstream\/10665\/44412\/1\/WHO_TRS_949_eng.pdf . Accessed 30 Nov 2016."},{"issue":"6","key":"481_CR12","doi-asserted-by":"crossref","first-page":"e1674","DOI":"10.1371\/journal.pntd.0001674","volume":"6","author":"A Musa","year":"2012","unstructured":"Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, et al. Sodium stibogluconate (ssg) & paromomycin combination compared to ssg for visceral leishmaniasis in east Africa: a randomised controlled trial. PLoS Negl Trop Dis. 2012;6(6):e1674.","journal-title":"PLoS Negl Trop Dis."},{"key":"481_CR13","unstructured":"Pharmacy and Poisons Board. Guidelines for the National Pharmacovigilance System in Kenya. Ministry of Medical Services and Ministry of Public Health and Sanitation Kenya; 2009."},{"key":"481_CR14","unstructured":"CIOMS. Reporting adverse drug reactions: definitions of terms and criteria for their use. Crusius ZBRBI, Venulet JGGKJ, editors. 1999. p. 170."},{"key":"481_CR15","unstructured":"Uppsala Monitoring Centre. Safety Monitoring of Medicinal Products, Guidelines for setting up and running a Pharmacovigilance Centre. the Uppsala Monitoring Centre; 2000."},{"key":"481_CR16","unstructured":"Administration H, Authority C. Guideline for Adverse Drug Events Monitoring (Pharmacovigilance) Third Edition Food, Medicine and Healthcare Administration and Control Authority of Ethiopia. 2014."},{"issue":"12","key":"481_CR17","first-page":"43","volume":"2","author":"R Arora","year":"2011","unstructured":"Arora R, Kapoor R, Gill NS, Aggarwal A, Rana AC. Pharmacovigilance: a way for better tomorrow. Int Res J Pharm. 2011;2(12):43\u20136.","journal-title":"Int Res J Pharm."},{"issue":"11","key":"481_CR18","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s40264-015-0331-7","volume":"38","author":"CK Suku","year":"2015","unstructured":"Suku CK, Hill G, Sabblah G, Darko M, Muthuri G, Abwao E, et al. Experiences and lessons from implementing cohort event monitoring programmes for antimalarials in four african countries: results of a questionnaire-based survey. Drug Saf. 2015;38(11):1115\u201326.","journal-title":"Drug Saf."},{"key":"481_CR19","unstructured":"MedDRA MSSO. Introductory Guide MedDRA Version 14.0. MSSO-DI-6003-14.0.0 March 2011. Available from: http:\/\/www.meddra.org\/sites\/default\/files\/guidance\/file\/intguide_14_0_english.pdf . Accessed 30 Nov 2016."},{"key":"481_CR20","unstructured":"WHO. A Practical Handbook on the Pharmacovigilance of Antimalarial Medicines. A Practical Handbook on the Pharmacovigilance of Antimalarial Medicines. 2007. p. 23."},{"key":"481_CR21","doi-asserted-by":"crossref","unstructured":"WHO. A practical handbook on the pharmacovigilance of medicines used in the treatment of tuberculosis, Enhancing the safety of the tb patient. 2012. p. 91.","DOI":"10.1038\/clpt.2012.24"},{"key":"481_CR22","unstructured":"WHO. A practical handbook on the pharmacovigilance of antiretroviral medicines. 2013. p. 23."},{"issue":"9","key":"481_CR23","doi-asserted-by":"crossref","first-page":"e3134","DOI":"10.1371\/journal.pntd.0003134","volume":"8","author":"R Omollo","year":"2014","unstructured":"Omollo R, Ochieng M, Mutinda B, Omollo T, Owiti R, Okeyo S, et al. Innovative approaches to clinical data management in resource limited settings using open-source technologies. PLoS Negl Trop Dis. 2014;8(9):e3134.","journal-title":"PLoS Negl Trop Dis."},{"key":"481_CR24","first-page":"2","volume":"4","author":"G Dawit","year":"2013","unstructured":"Dawit G. A review on biology, epidemiology and public health significance of leishmaniasis. J Bacteriol Parasitol. 2013;4:2\u20137.","journal-title":"J Bacteriol Parasitol."},{"key":"481_CR25","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1469-0691.2002.00456.x","volume":"8","author":"S Cesur","year":"2002","unstructured":"Cesur S, Bahar K, Erekul S. Death from cumulative sodium stibogluconate toxicity on Kala-Azar. Clin Microbiol Infect. 2002;8:606.","journal-title":"Clin Microbiol Infect."},{"issue":"10","key":"481_CR26","first-page":"4","volume":"4","author":"AM Musa","year":"2010","unstructured":"Musa AM, Younis B, Fadlalla A, Royce C, Balasegaram M, Wasunna M, et al. Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study. PLoS Negl Trop Dis. 2010;4(10):4\u201310.","journal-title":"PLoS Negl Trop Dis."},{"issue":"5","key":"481_CR27","doi-asserted-by":"crossref","first-page":"e2875","DOI":"10.1371\/journal.pntd.0002875","volume":"8","author":"E Diro","year":"2014","unstructured":"Diro E, Lynen L, Mohammed R, Boelaert M, Hailu A, van Griensven J. High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia. PLoS Negl Trop Dis. 2014;8(5):e2875.","journal-title":"PLoS Negl Trop Dis."},{"issue":"10","key":"481_CR28","doi-asserted-by":"crossref","first-page":"e709","DOI":"10.1371\/journal.pntd.0000709","volume":"4","author":"A Hailu","year":"2010","unstructured":"Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, et al. Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial. PLoS Negl Trop Dis. 2010;4(10):e709.","journal-title":"PLoS Negl Trop Dis."},{"key":"481_CR29","doi-asserted-by":"crossref","unstructured":"Khalil EAG, Weldegebreal T, Younis BM, Omollo R, Musa AM, Hailu W, et al. Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial. PLoS Negl Trop Dis. 2014;8(1):e2613.","DOI":"10.1371\/journal.pntd.0002613"},{"key":"481_CR30","doi-asserted-by":"crossref","unstructured":"den Boer M, Argaw D, Jannin J, Alvar J. Leishmaniasis impact and treatment access. Clin Microbiol Infect. Eur Soc Clin Microbiol Infect Dis. 2011;17(10):1471\u20137.","DOI":"10.1111\/j.1469-0691.2011.03635.x"},{"key":"481_CR31","unstructured":"Identifier: C go., NCT02011958. Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. 2016. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02011958?term=HIV+and+Visceral+Leishmaniasis%26rank=3 . Accessed 13 Oct\u00a02016."},{"key":"481_CR32","doi-asserted-by":"crossref","unstructured":"Boelaert M, Verdonck K, Menten J, Sunyoto T, van Griensven J, Chappuis F, et al. Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease. Cochrane database Syst Rev. 2014;6(6):CD009135.","DOI":"10.1002\/14651858.CD009135.pub2"},{"issue":"6","key":"481_CR33","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1532-5415.1999.tb01603.x","volume":"47","author":"BM Psaty","year":"1999","unstructured":"Psaty BM, Koepsell TD, Lin D, Weiss NS, Siscovick DS, Rosendaal FR, et al. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc. 1999;47(6):749\u201354.","journal-title":"J Am Geriatr Soc."},{"issue":"10","key":"481_CR34","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1046\/j.1365-3156.1999.00473.x","volume":"4","author":"A Sheik-Mohamed","year":"1999","unstructured":"Sheik-Mohamed A, Velema JP. Where health care has no access: the nomadic populations of sub-Saharan Africa. Trop Med Int Heal. 1999;4(10):695\u2013707.","journal-title":"Trop Med Int Heal."},{"key":"481_CR35","first-page":"105","volume":"5","author":"D Jacob","year":"2013","unstructured":"Jacob D, Marr\u00f3n B, Rutherford PA, Corporation BH. Pharmacovigilance as a tool for safety and monitoring: a review of general issues and the specific challenges with end-stage renal failure patients. Drug Healthc Patient Saf. 2013;5:105\u201312.","journal-title":"Drug Healthc Patient Saf."},{"issue":"4","key":"481_CR36","first-page":"1","volume":"6","author":"L Sczech","year":"2012","unstructured":"Sczech L. Designing a strategy for kidney toxicity monitoring in clinical trials: pitfalls and solutions. Pharmacovigil Rev. 2012;6(4):1\u20133.","journal-title":"Pharmacovigil Rev."},{"key":"481_CR37","doi-asserted-by":"crossref","unstructured":"Bate AES. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 18(6):427\u201336.","DOI":"10.1002\/pds.1742"},{"key":"481_CR38","first-page":"2","volume":"3","author":"World Health Organization","year":"2005","unstructured":"World Health Organization. The use of the WHO-UMC system for standardized case causality assessment. Uppsala Uppsala Monit Cent. 2005;3:2\u20137.","journal-title":"Uppsala Uppsala Monit Cent."},{"issue":"8","key":"481_CR39","doi-asserted-by":"crossref","first-page":"e0004896","DOI":"10.1371\/journal.pntd.0004896","volume":"10","author":"S Hirve","year":"2016","unstructured":"Hirve S, Boelaert M, Matlashewski G, Mondal D, Arana B, Kroeger A, et al. Transmission dynamics of visceral leishmaniasis in the indian subcontinent\u2014a systematic literature review. PLoS Negl Trop Dis. 2016;10(8):e0004896.","journal-title":"PLoS Negl Trop Dis."},{"key":"481_CR40","unstructured":"WHO. Costs of medicines in current use for the treatment of leishmaniasis. Technical Report series (TRS). 2010."},{"issue":"1","key":"481_CR41","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/S2214-109X(13)70118-9","volume":"2","author":"D Mondal","year":"2014","unstructured":"Mondal D, Alvar J, Hasnain MG, Hossain MS, Ghosh D, Huda MM, et al. Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study. Lancet Glob Health. 2014;2(1):e51\u20137.","journal-title":"Lancet Glob Health"},{"issue":"3","key":"481_CR42","doi-asserted-by":"crossref","first-page":"513","DOI":"10.4269\/ajtmh.14-0259","volume":"92","author":"S Sundar","year":"2015","unstructured":"Sundar S, Singh A, Rai M, Chakravarty J. Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: a phase 2 study. Am J Trop Med Hyg. 2015;92(3):513\u20137.","journal-title":"Am J Trop Med Hyg."},{"key":"481_CR43","doi-asserted-by":"crossref","unstructured":"Sundar S, Chakravarty J, Agarwal D, et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med. 2010;362(2):504\u201312.","DOI":"10.1056\/NEJMoa0903627"},{"key":"481_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0004880","volume":"10","author":"M Wasunna","year":"2016","unstructured":"Wasunna M, Njenga S, Balasegaram M, Alexander N, Omollo R, Edwards T, et al. Efficacy and safety of am bisome in combination with sodium stibogluconate or miltefosine and miltefosine monotherapy for african visceral leishmaniasis: phase II randomized trial. PLoS Negl Trop Dis. 2016;10:1\u201318.","journal-title":"PLoS Negl Trop Dis."},{"key":"481_CR45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40264-012-0014-6","volume":"36","author":"SN Pal","year":"2013","unstructured":"Pal SN, Duncombe C, Falzon D, Olsson S. WHO strategy for collecting safety data in public health programmes : complementing spontaneous reporting systems. Drug Saf. 2013;36:75\u201381.","journal-title":"Drug Saf."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0481-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-016-0481-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0481-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T04:25:31Z","timestamp":1568694331000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-016-0481-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,9]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["481"],"URL":"https:\/\/doi.org\/10.1007\/s40261-016-0481-0","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,9]]}}}